Yingao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yingao Zhang has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- David M. Gershenson
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
28 shared publications - Lauren Patterson Cobb
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
28 shared publications - Shannon Neville Westin
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
28 shared publications - Amadeo B. Biter
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3
27 shared publications - Amber Johnson
The University of Texas MD Anderson Cancer Center 2 Molecular Diagnostics Laboratory, Division of Pathology and Laboratory Medicine Houston, Texas
27 shared publications - Amir Anthony Jazaeri
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
27 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
COVID-19 mRNA vaccination is associated with improved survival in patients with endometrial cancer undergoing treatment with immune checkpoint inhibitors
ObjectivesReceipt of a COVID-19 mRNA vaccine before starting immune checkpoint inhibitor (ICI) treatment has been recently shown to be associated with improved survival in patients with lung cancer and melanoma. The primary objective of this study was to explore this potential association in patients receiving ICI for endometrial cancer.MethodsWe conducted a single-institution retrospective cohort study of patients diagnosed with endometrial cancer who received at least 3 ICI cycles between 2020-2025. The primary outcome was overall survival (OS). Secondary outcomes included adjusted progression-free survival (aPFS) and adjusted overall survival (aOS) with the starting point for survival calculations set on the date of ICI initiation.ResultsOur final analysis included 187 patients, with a median follow-up time of 35.2 months. Most patients had advanced-stage disease (68%, n=128) and received ICI in the recurrent setting (54%, n=101). Overall, we observed that vaccinated patients within 180 days of ICI initiation or during treatment (37%, n=70) had a longer median OS (123.8 vs 63.0 m, p=0.005) and aOS (62.5 vs 35.2 m, p=0.02), though aPFS was not different. On multivariable analyses, vaccination within 180 days was independently associated with improved OS (aHR 0.41, 95% CI 0.23-0.74) and aOS (aHR 0.39, 95% CI 0.20-0.72).ConclusionReceipt of a COVID-19 mRNA vaccine is associated with improved OS and aOS in patients undergoing ICI treatment for endometrial cancer. Our data supports the inclusion of mRNA vaccines into future trial protocols. Further, this positive association may be tumor-agnostic and should be investigated in other cancer types.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCOVID-19 mRNA vaccination is associated with improved survival in patients with endometrial cancer undergoing treatment with immune checkpoint inhibitors
ObjectivesReceipt of a COVID-19 mRNA vaccine before starting immune checkpoint inhibitor (ICI) treatment has been recently shown to be associated with improved survival in patients with lung cancer and melanoma. The primary objective of this study was to explore this potential association in patients receiving ICI for endometrial cancer.MethodsWe conducted a single-institution retrospective cohort study of patients diagnosed with endometrial cancer who received at least 3 ICI cycles between 2020-2025. The primary outcome was overall survival (OS). Secondary outcomes included adjusted progression-free survival (aPFS) and adjusted overall survival (aOS) with the starting point for survival calculations set on the date of ICI initiation.ResultsOur final analysis included 187 patients, with a median follow-up time of 35.2 months. Most patients had advanced-stage disease (68%, n=128) and received ICI in the recurrent setting (54%, n=101). Overall, we observed that vaccinated patients within 180 days of ICI initiation or during treatment (37%, n=70) had a longer median OS (123.8 vs 63.0 m, p=0.005) and aOS (62.5 vs 35.2 m, p=0.02), though aPFS was not different. On multivariable analyses, vaccination within 180 days was independently associated with improved OS (aHR 0.41, 95% CI 0.23-0.74) and aOS (aHR 0.39, 95% CI 0.20-0.72).ConclusionReceipt of a COVID-19 mRNA vaccine is associated with improved OS and aOS in patients undergoing ICI treatment for endometrial cancer. Our data supports the inclusion of mRNA vaccines into future trial protocols. Further, this positive association may be tumor-agnostic and should be investigated in other cancer types.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Histologic distribution of gynecologic cancers with RAS mutations (n=523)
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Histologic distribution of gynecologic cancers with RAS mutations (n=523)
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Co-mutation analysis of RAS mutations in gynecologic cancers
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Co-mutation analysis of RAS mutations in gynecologic cancers
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Clinical efficacy of KRAS G12C inhibitors in gynecologic cancer patients with KRAS G12C mutation
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Clinical efficacy of KRAS G12C inhibitors in gynecologic cancer patients with KRAS G12C mutation
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Clinical efficacy of RAS + MAPK pathway inhibitors in patients with RAS-mutated gynecologic cancers: (a) histologic breakdown and (b) multivariable analysis for overall survival in type 1, type 2, and low-grade serous ovarian cancers.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Clinical efficacy of RAS + MAPK pathway inhibitors in patients with RAS-mutated gynecologic cancers: (a) histologic breakdown and (b) multivariable analysis for overall survival in type 1, type 2, and low-grade serous ovarian cancers.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Prevalence of RAS mutations in gynecologic cancers by histology for (a) NRAS and (b) HRAS. In parentheses, mut (n)/histology (n)
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Prevalence of RAS mutations in gynecologic cancers by histology for (a) NRAS and (b) HRAS. In parentheses, mut (n)/histology (n)
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Co-mutation analysis of gynecologic cancers with KRAS G12C-mutation
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Co-mutation analysis of gynecologic cancers with KRAS G12C-mutation
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Clinical efficacy of RAS + MAPK pathway inhibitors in patients with RAS-mutated gynecologic cancers: (a) histologic breakdown and (b) multivariable analysis for overall survival in type 1, type 2, and low-grade serous ovarian cancers.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Clinical efficacy of RAS + MAPK pathway inhibitors in patients with RAS-mutated gynecologic cancers: (a) histologic breakdown and (b) multivariable analysis for overall survival in type 1, type 2, and low-grade serous ovarian cancers.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
(a) Univariate and (b) multivariable analyses of factors associated with overall survival in gynecologic cancer patients undergoing somatic molecular profiling
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
(a) Univariate and (b) multivariable analyses of factors associated with overall survival in gynecologic cancer patients undergoing somatic molecular profiling
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Histologic distribution of gynecologic cancers by RAS mutation (expanded histologic categories, percentages by row)
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Histologic distribution of gynecologic cancers by RAS mutation (expanded histologic categories, percentages by row)